Cystic fibrosis drug halts lung damage in young children
Orkambi targets the most common mutation for cystic fibrosis, but is not available in the UK on the NHS. Now a trial has shown promising effects in children
Comments are closed.
The GMA is a member of the Confederation of African Medical Associations and Societies (CAMAS), Commonwealth Medical Association (CMA) and the World Medical Association).
Copyright Ghana Medical Association 2017.